|Terrorist plot bumps network news coverage of tissue-engineered skin momentarily|
|Saturday, 30 October 2010 06:10|
Shares of Regenicin (OTC:WDST) closed up at $1.05 +0.13 (14.75%) after trading as high as $1.10 during Friday's session. Investors exchanged nearly 1.2 million shares of the newly trading micro-cap company which recently secured the license for the new science from the Swiss-based pharmaceutical leader Lonza. Regenicin is reportedly preparing to advance a ground-breaking engineered skin substitute technology to commercialization with, according to our sources, the full support and backing of the U.S. military.
Investors who tuned in to ABC World News Tonight with Diane Sawyer on Friday Night hoping to catch a glimpse of the new technology were dissapointed to find that unplanned coverage of a new, credible terrorist plot against the United States had bumped many of the news stories producers had lined up for the Friday night broadcast.
BioMedReports reached out to officials who informed us that the story had "only been bumped temporarily" and we learned for the first time that Regenicin's Chief Executive Officer, Randall McCoy will be featured/interviewed as part of the news piece which will now be re-scheduled to air on the network. Sources told BioMedReports late Friday evening: "Obviously, we cannot control the media, but we do know the story will air shortly. It could be this weekend, it could be during the week. All we can do is monitor the situation." We will also monitor the airwaves and keep our readers posted as soon as we see or hear anything.
In the past, similarly priced companies in the same sector, like StemCells, Inc. (NASDAQ:STEM), have traded as high as $6+ dollars after major news media has focused attention to their technologies.
Disclosure: Long WDST